Safety issues for Novartis CAR-T therapy main focus of FDA – BioPharma Dive
|
Safety issues for Novartis CAR–T therapy main focus of FDA
BioPharma Dive The Food and Drug Administration plans to ask an independent panel of experts to focus their attention on the safety profile of Novartis' experimental CAR–T therapy tisagenlecleucel when they meet to review the leukemia treatment at a public meeting … |
